GLP-1 Medication and Pancreatitis: Understanding the Risk

Pancreatitis, or inflammation of the pancreas, is a recognised but uncommon side effect of GLP-1 medicines including Mounjaro (tirzepatide), Wegovy and Ozempic (semaglutide) and Saxenda (liraglutide). In January 2026 the MHRA strengthened the warnings for the whole class to highlight rare reports of severe necrotising and fatal pancreatitis. For any individual the risk is very small, but it matters because early treatment improves outcomes. The single most important thing to know is the warning sign: severe, persistent tummy pain that may spread to your back needs urgent medical attention.

What is pancreatitis?

The pancreas is a gland that sits behind the stomach. It produces digestive enzymes that help break down food, and hormones including insulin that control blood sugar.

In acute pancreatitis, the pancreas becomes suddenly inflamed. The NHS explains that most people improve within about a week and have no further problems, but some develop severe complications that need intensive hospital care. In a small proportion of severe cases, part of the pancreas tissue dies, which is called necrotising pancreatitis. This is serious and can be life-threatening.

Chronic pancreatitis is a different, long-term condition in which the pancreas is permanently damaged, most often linked to long-term heavy alcohol use.

According to the NHS, the most common causes of acute pancreatitis in the UK are:

• Gallstones
• Drinking too much alcohol

Other causes include very high levels of fats in the blood (triglycerides), certain medicines, some infections, injury and, sometimes, no clear cause is found.

What the MHRA said in January 2026

On 29 January 2026, the MHRA published a Drug Safety Update for healthcare professionals and a press release for the public about GLP-1 medicines and pancreatitis. The key points were:

The update followed advice from the Pharmacovigilance Expert Advisory Group of the Commission on Human Medicines, which recommended that warnings be strengthened and made consistent across the class.

What the numbers mean, and what they do not

It is easy to misread Yellow Card figures, so it is worth being careful.

• A report is not proof. A Yellow Card report means someone suspected a link between a medicine and a health problem. It does not confirm that the medicine caused it. Some people would have developed pancreatitis anyway, for example because of gallstones or alcohol.
• Reports are not a rate. Because not every case is reported, and because the number of people using these medicines has grown rapidly, you cannot divide reports by prescriptions to calculate an exact risk.
• The context matters. Set against tens of millions of packs dispensed, the number of reports is small. This is why the MHRA describes the risk as very small for any individual, while still wanting everyone to know the warning signs.

The UK SmPCs for individual medicines list pancreatitis among their uncommon or rare side effects. Exact frequency categories vary between products and are updated over time, so check the current SmPC or patient leaflet for your medicine.

Why might GLP-1 medicines be linked to pancreatitis?

Researchers do not fully understand the relationship, and it is likely to involve several overlapping factors.

Background risk in the people treated

People living with obesity or type 2 diabetes already have a higher underlying risk of pancreatitis than the general population. Obesity and diabetes are both associated with gallstones and raised triglycerides, two established causes. This makes it hard to work out how much of the risk is due to the medicine and how much to the underlying conditions.

Gallstones and rapid weight loss

Rapid weight loss from any cause, including diets and bariatric surgery, increases the risk of gallstones. A gallstone that blocks the duct shared by the gallbladder and pancreas can trigger acute pancreatitis. GLP-1 medicines are also associated with gallbladder problems in their own right. Our guide to GLP-1 medication and gallbladder problems explains this in detail.

Effects on the pancreas itself

GLP-1 receptors are present in the pancreas. The SmPCs note that raised levels of the pancreatic enzymes lipase and amylase have been seen in people taking these medicines. Without other signs and symptoms of acute pancreatitis, raised enzymes alone are not considered to predict it, and routine enzyme testing is not generally recommended for people without symptoms.

Genetic susceptibility

One of the open questions is why only a small number of people are affected. In June 2025, the MHRA's Yellow Card Biobank, run with Genomics England, began recruiting adults who had been hospitalised with acute pancreatitis while taking a GLP-1 medicine. Participants were asked to provide a saliva sample so researchers could look for genetic factors that might increase susceptibility. Recruitment was due to run until January 2026. Results may help regulators and prescribers identify people at higher risk in future; check the MHRA website for updates.

Symptoms: how pancreatitis differs from everyday side effects

This is the most practically important section of this guide. Nausea, vomiting, indigestion and mild tummy discomfort are very common on GLP-1 medicines, especially after starting or increasing the dose. The MHRA has acknowledged that this overlap can make early pancreatitis harder to recognise.

The NHS describes the main symptom of acute pancreatitis as suddenly getting severe pain in the centre of your tummy. Some people find leaning forward eases it slightly.

Who might be at higher risk?

There is no reliable way to predict who will develop pancreatitis on a GLP-1. However, prescribers will want to know about factors that raise background risk. Tell your prescriber honestly if any of these apply:

• Previous pancreatitis. The SmPCs state that these medicines have not been studied in people with a history of pancreatitis and should be used with caution. The MHRA repeats this advice.
• Gallstones or previous gallbladder problems, including attacks of biliary colic.
• High triglycerides, especially very high levels.
• Alcohol use above recommended limits. Heavy drinking is a leading cause of pancreatitis. See our guide to Mounjaro and alcohol.
• Other medicines known to be associated with pancreatitis. Your prescriber or pharmacist can review these.
• A family history of pancreatitis or inherited lipid disorders.

These factors do not automatically rule out treatment. They are part of the conversation your prescriber should have with you before deciding whether a GLP-1 is appropriate and safe. For a wider overview, read who should not take GLP-1 medicines.

How is pancreatitis diagnosed and treated?

If pancreatitis is suspected, you will usually be assessed in hospital. The NHS explains that diagnosis is based on your symptoms, a physical examination and blood tests, sometimes with a scan such as an ultrasound or CT.

Treatment for acute pancreatitis is mainly supportive. According to the NHS, this usually involves:

• Fluids given through a drip to prevent dehydration
• Pain relief
• Oxygen if needed
• Nutritional support, sometimes through a feeding tube if you cannot eat
• Treating the underlying cause, for example removing gallstones or the gallbladder

Most people with mild acute pancreatitis recover within about a week. Severe cases may need longer hospital stays and intensive care.

What happens to your GLP-1 treatment

The guidance here is clear and consistent across the MHRA Drug Safety Update and the UK SmPCs:

1. If pancreatitis is suspected, the GLP-1 or GLP-1/GIP medicine should be stopped immediately.
2. If pancreatitis is confirmed, the medicine should not be restarted.

This applies across the class, so switching from one GLP-1 medicine to another after confirmed pancreatitis is generally not appropriate. Your GP or specialist can discuss alternative ways to manage weight or diabetes. This could include lifestyle support, other medicines, or, for some people, referral to specialist weight-management services or bariatric surgery assessment. Our guide comparing GLP-1 medicines and bariatric surgery explains the options.

Reducing your risk while on treatment

Nothing can remove the risk entirely, but sensible steps help reduce background risk and make sure problems are picked up early.

• Give a complete medical history to your prescriber, including any past pancreatitis, gallstones, blood fat problems and alcohol intake.
• Follow the titration schedule. Dose increases are usually made every four weeks to help your body adjust. Do not increase faster or use more than prescribed.
• Keep alcohol within limits, or avoid it. The UK Chief Medical Officers advise not regularly drinking more than 14 units a week.
• Stay hydrated, especially if you have vomiting or diarrhoea. See our guide to hydration on GLP-1 medication.
• Learn the warning signs and make sure people close to you know them too.
• Use only regulated prescribers and pharmacies. Unlicensed or fake products may contain the wrong dose or unknown substances, and you will not have proper clinical follow-up. The MHRA warns strongly against obtaining these medicines from social media, beauty salons or unregulated websites. Our guide to fake weight-loss jabs explains the risks.
• Keep your GP informed if you are prescribed privately, so your medical record is accurate.

Clinical trials versus real-world reports

People often ask why pancreatitis did not look like a major problem in the big clinical trials, yet regulators are now strengthening warnings. There are a few reasons this happens with many medicines, not just GLP-1s.

• Trials did show a small signal. For example, the Wegovy SmPC reports that adjudication-confirmed acute pancreatitis occurred in 0.2% of people on semaglutide 2.4 mg in the phase 3a weight-management trials, compared with less than 0.1% on placebo.
• Trials are large, but rare events are rarer still. Even a trial with several thousand participants may see only a handful of pancreatitis cases in each group. That is not enough to detect a small difference reliably, and certainly not enough to understand the most severe forms.
• Trial participants are selected. People with a history of pancreatitis, heavy alcohol use or other risk factors are often excluded, so the trial population may be at lower risk than everyone who goes on to use the medicine.
• Real-world use is far larger. Millions of people across the UK have now used GLP-1 medicines. Post-marketing surveillance, including the Yellow Card scheme, is designed to pick up rare and serious reactions that trials could not.
• Severity matters as well as frequency. The 2026 update did not say pancreatitis has become common. It said that some of the rare cases have been particularly severe, and that warnings should reflect this consistently across the class.

This is how medicine safety monitoring is supposed to work: product information evolves as evidence accumulates. It is one reason to read the patient leaflet that comes with each new supply, as it may have been updated since you started.

Questions to ask your prescriber

Whether you are considering treatment or already taking a GLP-1, these questions can help you have an informed conversation:

• Given my medical history, is my risk of pancreatitis higher than average?
• Do I need any blood tests, such as triglycerides, before starting?
• Should I be cautious about alcohol, and how much is reasonable for me?
• What should I do if I have tummy pain and I am not sure whether it is a normal side effect?
• If I am prescribed privately, how will you share information with my GP?
• What would happen to my treatment plan if I developed gallstones or pancreatitis?

A responsible prescriber, whether NHS or private, should welcome these questions and give you clear answers. If you feel you are not getting proper screening or follow-up, that is a reason to raise concerns or seek a second opinion.

After an episode of pancreatitis

If you have had pancreatitis while taking a GLP-1 medicine, recovery and next steps will be guided by your hospital team and GP. Common elements include:

• Finding the cause. Clinicians will usually look for gallstones, check blood fats and ask about alcohol, as well as considering the medicine. The answer affects what happens next.
• Treating gallstones if they were responsible, which often means removing the gallbladder.
• Not restarting the GLP-1 if pancreatitis was confirmed, in line with MHRA and SmPC advice.
• Planning alternative weight or diabetes care. For people with type 2 diabetes, other glucose-lowering medicines are available. For weight management, your GP can discuss lifestyle programmes and specialist services.
• Reporting the reaction through the Yellow Card scheme, if this has not already been done.

It is understandable to feel frustrated if treatment that was working has to stop. Talking it through with your GP, and with a specialist weight-management service where available, can help you plan the next stage.

Putting the risk in perspective

For most people prescribed a GLP-1 medicine for weight management or type 2 diabetes, the potential health benefits are substantial, and the risk of pancreatitis is small. But "small" does not mean "zero", and the MHRA's 2026 update reflects the fact that a few cases have been very serious.

The balance of benefits and risks is different for every person. It depends on your weight, health conditions, history and preferences. This is why the decision to start, continue or stop treatment belongs to you and your prescriber together, based on a proper clinical assessment.

If you are trying to understand how different regulated providers handle medical screening and ongoing safety checks, our provider comparison sets out the services available. You can also read our Mounjaro side effects guide, the dedicated page on Mounjaro and pancreatitis, or our hub on weight-loss injections for more background.

Reporting suspected side effects

The MHRA relies on Yellow Card reports to monitor medicine safety, and these reports directly led to the 2026 strengthened warnings. If you think you have had pancreatitis or any other side effect from a GLP-1 medicine, you can report it through the Yellow Card website or app. Healthcare professionals are asked to report all suspected cases, especially serious or fatal ones, with as much detail as possible about medical history, other medicines and timing.

You can also report if you suspect a product is not genuine.

When to speak to a professional

Call 999 or go to A&E immediately if you have:

• Severe, persistent abdominal pain, especially if it spreads to your back, with or without nausea and vomiting. Stop taking your GLP-1 and tell staff you are on it.
• Tummy pain with a high temperature, fast heartbeat or feeling very unwell
• Yellowing of the skin or the whites of the eyes (jaundice), especially with pain or fever
• Vomiting blood or passing black, tarry stools
• Signs of severe dehydration, such as not peeing, confusion or fainting
• Signs of a severe allergic reaction, such as swelling of the face, lips or throat, or difficulty breathing

Call NHS 111 or speak to your prescriber urgently if you have:

• Tummy pain that is worse than your usual side effects or is not settling
• Repeated vomiting and you cannot keep fluids down
• Signs of dehydration, such as dark urine, peeing less, dizziness or a dry mouth
• Pain in the upper right of your tummy after fatty meals, which may suggest gallstones

Speak to your prescriber or GP before starting or continuing treatment if:

• You have ever had pancreatitis, gallstones or very high triglycerides
• You drink alcohol above recommended limits
• You have been in hospital with tummy problems since starting your GLP-1

If you are struggling with your mental health or having thoughts of suicide, call NHS 111 (option 2 for mental health in many areas), contact Samaritans free on 116 123, or call 999 in an emergency.